Senior Expert, Julie Barnhill, Ph.D., to share practical strategies for ensuring GxP compliance in virtual and hybrid pharma companies
MINNEAPOLIS, MN / ACCESS Newswire / February 20, 2026 / As pharmaceutical companies increasingly rely on outsourced operations, maintaining GxP compliance has become a critical and challenging element of sponsorship oversight. Pace® Life Sciences, a U.S.-based contract development and manufacturing organization (CDMO) and a division of Pace®, a Science and Technology Company, is hosting a free, live virtual webinar on February 24th, 2026 at 11 AM EST, "Quality by Design for Outsourced Pharmaceutical Operations" led by Julie Barnhill, Ph.D., drawing on decades of hands-on experience supporting companies through all phases of drug development.
Attendees will learn how to:
Establish a right-sized Quality Management System (QMS) aligned with organizational stage and risk profile
Apply a risk-based vendor qualification strategy
Implement effective oversight mechanisms to ensure transparency and data integrity
Strengthen quality agreements and coordinate change management across multiple vendors
Leverage cloud-based systems to enhance real-time communication and compliance visibility
This webinar is designed to help pharma companies move beyond paper compliance and implement oversight models that work in real world, multivendor environments to ensure GxP compliance.
Registration Information
February 24th at 11 AM EST - Registration Link
Pace® is a portfolio company of Leonard Green & Partners and Los Angeles-based Aurora Capital Partners.
###
About Julie Barnhill, PhD
Dr. Barnhill is a Senior Consultant at Pace® Life Sciences specializing in GxP compliance from preclinical through commercial drug development. She provides strategic QA leadership for virtual and hybrid biopharma companies, including building quality systems, conducting GxP audits, and preparing organizations for FDA inspections.
Prior to Pace®, Dr. Barnhill held senior quality leadership roles at Osiris Therapeutics, Alpharma (now Actavis), and Chesapeake Biological Laboratories (now Emergent). She serves on the Board of the PDA Capital Area Chapter, is Adjunct Graduate Faculty at Johns Hopkins University, and is a Course Director with CfPIE. She earned her Ph.D. from the University of Pennsylvania and her B.S. from Trinity College.
About Pace® Life Sciences
Pace® Life Sciences provides a full suite of contract CMC development, clinical trials materials manufacturing, regulatory compliance, consulting, and facility support services to the pharmaceutical, biopharmaceutical, and gene therapy industries. Our network of CDMO sites consists of GMP analytical testing laboratories and manufacturing support service centers. Our experienced, highly trained industry experts and our investment in state-of-the-art development and manufacturing facilities emphasize our commitment to efficiently advancing client programs through the clinic to commercialization. We are dedicated to delivering the best and most reliable services with positive customer experiences across all channels of our business.
Media Contacts
Chelsea Simpson - Associate Director, Marketing
Chelsea.Simpson@pacelabs.com
Brooke Schwartzel - Brand & Communications Manager
Brooke.Schwartzel@pacelabs.com | 612.656.2241
SOURCE: Pace® Analytical
View the original press release on ACCESS Newswire
